Section Arrow
Quote
BLSM.NASDAQ
- BlossomHill Therapeutics, Inc.
Quotes are at least 15-min delayed:2026/11/06 21:16 EST
Regular Hours
Last
 13.5
+1.15 (+9.31%)
Day High 
14.09 
Prev. Close
12.35 
1-M High
20.06 
Volume 
174.33K 
Bid
12.2
Ask
13.57
Day Low
12.14 
Open
12.29 
1-M Low
11.02 
Market Cap 
392.54M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 14.18 
20-SMA 14.81 
50-SMA 18.58 
52-W High 27.99 
52-W Low 11.02 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.66/-2.99
Enterprise Value
414.94M
Balance Sheet
Book Value Per Share
-5.50
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
KPTIKaryopharm Therapeutics Inc.0.0549-0.0052-8.65%-- 
INOInovio Pharmaceuticals1.215-0.235-16.21%-- 
LABTLakewood-Amedex Biotherapeutics Inc0.3863-0.1543-28.54%-- 
CDTCdt Equity Inc1.31+0.464+54.85%0PE
MRNAModerna254.19+12.73+5.27%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.